OBJECTIVES: The objective of this study was to assess to what extent HTA outcomes have been incorporated in drug reimbursement decision-making process in Poland. METHODS: To assess HTA impact, following research questions were investigated: 1) How many different health problems currently prioritized by policy-makers have received HTA Agency’s attention? and 2) How many different drug technologies with HTA recommendations have been included on the current reimbursement lists? In total, 83 HTA recommendations disseminated by the Appraisal Body of HTA Agency in Poland concerning drug technologies in the period from September 6, 2007 until February 2, 2009 were studied.  The most recent reimbursement lists issued 23 February 2009 by Ministry of Health and 7 July 2008 by National Health Fund were utilized. The list of prioritised health problems issued 23 February 2009 by Ministry of Health was studied as well.  HTA recommendations were divided into positive and negative guidance. Drug technologies, appraised by HTA Agency, were classified into two groups: 1) eligible (a drug technology indicated for a prioritized health problem), and 2) not eligible (a drug technology not indicated for a prioritized health problem). RESULTS: As many as 59% and 54% of different indications were prioritized by Ministry of Health without any input from HTA process. In total, 40 negative and 43 positive HTA recommendations were issued. Only 18 of 43 (42%) drug technologies with a positive guidance were included on the reimbursement lists. At the same time as many as 6 of 40 (15%) of medicines with negative HTA recommendation were listed. In total, HTA Agency appraised 58 eligible and 25 non-eligible drug technologies. There were 32 positive HTA recommendations in the first group, of which 18 (56%) were included on the reimbursement lists. CONCLUSIONS: The HTA impact on drug reimbursement decisions in Poland is partially achieved and could be further enhanced.